预约演示
更新于：2026-06-08
Cabazitaxel Acetone
卡巴他赛
更新于：2026-06-08
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2010-06-17), |
最高研发阶段(中国)临床1期 |
特殊审评孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C48H63NO15 |
InChIKeyJXGFNOAMBPABCK-JVXKREHESA-N |
CAS号1426815-65-7 |
关联
138
项与 卡巴他赛 相关的临床试验NCT06738303
Carboplatin and Cabazitaxel Versus 177Lu-PSMA-617 in Patients With Aggressive, Metastatic Castrate-resistant Prostate Cancer (CATCH-177)
NCT06890832
A Phase-2, Open-label, Randomized, Parallel-Group, Three-Arm Study to Assess Efficacy and Safety of Cabazitaxel Lipid Tablet in Combination with Prednisone for the Treatment of Adult Men with Metastatic Castration-Resistant Prostate Cancer Previously Treated with a Docetaxel-containing Treatment Regimen
NCT06632977
PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)
100 项与 卡巴他赛 相关的临床结果
登录后查看更多信息
100 项与 卡巴他赛 相关的转化医学
登录后查看更多信息
100 项与 卡巴他赛 相关的专利（医药）
登录后查看更多信息
1,606
项与 卡巴他赛 相关的文献（医药）2026-06-01Clinical Genitourinary Cancer
Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer
Article
作者: Kim, Christopher ; Green, Lauren ; Hwang, Yunji ; Barata, Pedro C
INTRODUCTION:
Real-world overall survival (rwOS) are limited in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC) previously treated with both docetaxel and an androgen receptor pathway inhibitor (ARPI).
METHODS:
In the ConcertAI Patient360 database, we identified patients with mCRPC who initiated cabazitaxel or subsequent ARPI (abiraterone or enzalutamide) between 2018 and 2024 after prior treatment with at least one ARPI and docetaxel in the mCRPC setting. Using the Kaplan-Meier method, rwOS (95% CI, months) was estimated from initiation of cabazitaxel or subsequent ARPI until death or end of follow-up.
RESULTS:
Among 517 patients (median age: 68.8 years; white race: 70.0%; baseline prostate specific antigen (PSA) ≥ 100 ng/mL: 38.3%), cabazitaxel was more common (62.5%) than subsequent ARPIs (38.0%; abiraterone: 19.0%; enzalutamide: 18.6%). Cabazitaxel was more frequently used in a later line of therapy (LOT), compared to subsequent ARPIs; and patients receiving cabazitaxel had greater docetaxel exposure prior to or after mCRPC diagnosis, compared to patients with subsequent ARPIs. The study population was heterogeneous, representing varying stages of disease progression and multiple LOT, with a median rwOS of 10.4 months (95% CI, 9.3-11.4). The rwOS rates at 12, 24 and 36 months were 43.9%, 20.5% and 15.7%, respectively. Shorter rwOS was observed among patients with a greater number of prior LOTs, and higher Eastern Cooperative Oncology Group Performance Status (ECOG-PS), higher PSA, or elevated lactate dehydrogenase (LDH).
CONCLUSION:
In this descriptive study of patients with mCRPC previously treated with docetaxel and ARPI, median rwOS following cabazitaxel or subsequent ARPI was less than 1 year, highlighting a substantial unmet medical need among heavily pretreated patients who are candidates for these therapies.
2026-06-01Cardiovascular Toxicology
The Potential Protective Effects of Resveratrol Against Cabazitaxel-Induced Oxidative Stress and Cardiotoxicity in Rats
Article
作者: Li, Zongru ; Hassan, Hany ; Elfadadny, Ahmed ; Farag, Ahmed ; Tanaka, Takashi ; Mandour, Ahmed ; Khaled, Hadeer ; Tanaka, Ryou
Cabazitaxel, an anti-prostate cancer agent, is associated with dose-dependent cardiotoxicity mediated by oxidative stress. This study investigated cabazitaxel-induced cardiac injury, the utility of intraventricular pressure gradients for early detection, and the potential protective effects of resveratrol. Twenty male Sprague Dawley rats were allocated into four groups: control, therapeutic cabazitaxel (0.5 mg/kg/week, intraperitoneally), toxic cabazitaxel (1.5 mg/kg/week, intraperitoneally), and toxic cabazitaxel + resveratrol (1.5 mg/kg/week cabazitaxel + 10 mg/kg/day resveratrol, intraperitoneally) for 28 days. Cardiac function was assessed via conventional echocardiography, electrocardiography, and intraventricular pressure gradients under anesthesia. Blood samples and heart tissues were collected for further biochemical and histopathological evaluation. Toxic cabazitaxel administration induced significant RR prolongation and bradycardia compared with controls (RR: 0.21 ± 0.02 vs. 0.18 ± 0.02 s; heart rate: 285.88 ± 31.04 vs. 330.40 ± 27.24 bpm), accompanied by aortic dilatation (aortic diameter: 3.73 ± 0.29 vs. 3.28 ± 0.21 mm), reduced acceleration time to ejection time ratio (0.21 ± 0.04 vs. 0.32 ± 0.12), increased derivatives of reactive oxygen metabolites: 394.75 ± 63.47 vs. 324.80 ± 15.56 U.CARR), elevated platelet counts (121.10 ± 26.48 vs. 81.65 ± 6.49 104/µL), decreased hemoglobin levels (14.26 ± 2.02 vs. 17.66 ± 1.014 g/dL), along with structural myocardial damage. Resveratrol co-administration reduced derivatives of reactive oxygen metabolites (372.40 ± 33.02), normalized aortic diameter, and improved acceleration time to ejection time ratio (3.09 ± 0.40 mm; 0.28 ± 0.06), enhanced electrocardiographic parameters (RR: 0.17 ± 0.01 s; heart rate: 352.24 ± 20.567), restored hemoglobin and platelet counts (15.94 ± 1.39 g/dL; 98.38 ± 28.41 104/µL), and preserved myocardial architecture. However, intraventricular pressure gradient indices remained elevated, and persistent thinning of the left ventricular posterior wall at end-diastole and end-systole was observed. These findings suggest that resveratrol partially mitigates cabazitaxel-induced cardiotoxicity.
2026-06-01Health policy OPEN
Price transparency & out-of-pocket payments for medications: Implications of associated delivery fees in the United States
Article
作者: Kaye, Deborah R ; Scales, Charles D ; George, Daniel J ; Lee, Hui-Jie ; Bundorf, M Kate
Background:
Price transparency has been cited as a tool to reduce out-of-pocket (OOP) payments to patients. These tools for prescription drugs often focus on the price to patients for the drug alone. However, costs associated with drug delivery (i.e. infusion center fees, labs, etc) are often unknown and could impact the effectiveness of price transparency tools. Objective: To examine total OOP payments on day of drug receipt ("full day", i.e. drug + drug administration fees) out-of-pocket (OOP) payments associated with six first-line treatments for metastatic castrate resistant prostate cancer and compare these with payments for drug alone and by insurance type.
Methods:
Using the IBM Marketscan databases, we identify male patients who initiated treatment with one of six focus drugs (docetaxel, abiraterone, enzalutamide, sipuleucel-T, cabazitaxel, and radium-223) used to treat mCRPC from 07/01/2013-06/30/2019. We calculated total OOP payments on day of drug receipt (full day OOP payments) by drug type for six first line treatments. We then used a two-part model to assess the association of first-line therapy with OOP payments for the four most frequently prescribed during the study time period.
Results:
We find that there is variation in the proportion of payments for drug alone relative to full day payments across first-line treatments. However, regression-adjusted mean full day OOP payments are not statistically different across first-line treatments for mCRPC for the four most frequently prescribed drugs. There are differences in the likelihood that an individual will incur any OOP payment by first-line treatment type and by health plan type.
Conclusion:
These analyses suggest that when accounting for additional services required on the day of drug receipt, the amount a patient pays to receive a medication for mCRPC can be very different from the OOP payment for the drug alone; these payments also vary by drug and health plan type. Therefore, price transparency for drug alone may not lead to reduced OOP payments for patients.
100 项与 卡巴他赛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺癌 | 日本 | 2014-07-04 | |
| 转移性去势抵抗性前列腺癌 | 美国 | 2010-06-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 前列腺腺癌 | 临床3期 | 法国 | 2013-12-01 | |
| 局限性前列腺癌 | 临床3期 | 法国 | 2013-12-01 | |
| 尿路上皮癌 | 临床3期 | 英国 | 2013-01-01 | |
| 去势抵抗性前列腺癌 | 临床3期 | 美国 | 2011-05-05 | |
| 去势抵抗性前列腺癌 | 临床3期 | 日本 | 2011-05-05 | |
| 去势抵抗性前列腺癌 | 临床3期 | 丹麦 | 2011-05-05 | |
| 去势抵抗性前列腺癌 | 临床3期 | 芬兰 | 2011-05-05 | |
| 去势抵抗性前列腺癌 | 临床3期 | 秘鲁 | 2011-05-05 | |
| 去势抵抗性前列腺癌 | 临床3期 | 瑞典 | 2011-05-05 | |
| 骨病 | 临床2期 | 意大利 | 2018-03-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 1,618 | 壓網繭蓋夢鹹淵願餘蓋(窪顧築鹽顧網製觸繭夢) = 壓繭網壓獵選遞鏇糧襯 襯衊窪窪膚窪鏇觸築襯 (築遞積鬱繭餘獵窪遞窪 ) 更多 | 不佳 | 2026-05-29 | |||
壓網繭蓋夢鹹淵願餘蓋(窪顧築鹽顧網製觸繭夢) = 構選襯遞艱積夢築構獵 襯衊窪窪膚窪鏇觸築襯 (築遞積鬱繭餘獵窪遞窪 ) 更多 | |||||||
临床2期 | 61 | 淵獵製壓鹽選夢遞膚齋 = 選觸積廠醖夢齋夢齋淵 膚顧艱夢蓋鏇鬱衊餘鹹 (製衊襯築築觸鬱鹽鹹廠, 廠選蓋餘淵夢艱構廠鹽 ~ 艱鬱遞鏇選選顧齋襯顧) 更多 | - | 2026-05-26 | |||
临床3期 | 194 | 窪顧窪鬱糧築鹽鹽築襯(積淵鑰築鹹壓齋繭蓋鏇) = 糧製夢衊壓構積衊構遞 構鬱蓋繭淵衊蓋鏇網憲 (夢壓壓簾獵衊築願壓淵 ) | 积极 | 2026-04-01 | |||
ARPI | 窪顧窪鬱糧築鹽鹽築襯(積淵鑰築鹹壓齋繭蓋鏇) = 築顧繭齋構製艱遞積壓 構鬱蓋繭淵衊蓋鏇網憲 (夢壓壓簾獵衊築願壓淵 ) | ||||||
临床2期 | 28 | 淵襯蓋廠積艱壓觸壓糧 = 願顧觸鹹夢鹽淵艱艱鏇 觸艱窪網觸膚網獵艱鏇 (膚鏇窪夢繭糧獵積繭醖, 鑰網顧獵簾壓鹽餘鹹鹽 ~ 艱選膚鬱簾淵願繭鹹夢) 更多 | - | 2026-03-06 | |||
临床3期 | 761 | 遞衊顧糧醖蓋積餘簾網(齋築積網鏇網憲願鏇積) = 範憲齋鹽鏇築淵顧齋網 製壓願鹽醖鬱選蓋網鏇 (夢窪製鑰蓋築壓鬱醖選 ) 更多 | 不佳 | 2026-02-26 | |||
ADT + Radiotherapy ± Pelvic Radiotherapy | 遞衊顧糧醖蓋積餘簾網(齋築積網鏇網憲願鏇積) = 鬱襯遞選憲築獵獵顧鹹 製壓願鹽醖鬱選蓋網鏇 (夢窪製鑰蓋築壓鬱醖選 ) 更多 | ||||||
N/A | 28 | 構鹹蓋遞鹹鏇醖艱蓋築(鹽獵襯蓋鬱襯鏇網網願) = 網繭鑰憲衊鏇鏇構壓夢 構醖夢廠齋選鏇艱鏇觸 (鹹鏇壓鹽鏇衊範範獵鑰, 3.0 ~ 13.4) 更多 | 积极 | 2026-02-26 | |||
(PSA 50 responders to LuPSMA) | 構鹹蓋遞鹹鏇醖艱蓋築(鹽獵襯蓋鬱襯鏇網網願) = 遞繭鬱顧夢廠廠築構獵 構醖夢廠齋選鏇艱鏇觸 (鹹鏇壓鹽鏇衊範範獵鑰, 4.0 ~ NR) 更多 | ||||||
临床2期 | 223 | (Arm A (Abiraterone Acetate, Prednisone, Cabazitaxel)) | 獵獵構觸鹽繭憲鹽鬱窪(製觸蓋廠鹹繭鹹繭遞獵) = 鹽顧襯繭齋壓夢遞製構 遞鏇鹽鏇製鑰襯壓顧淵 (鏇鹹衊遞鏇齋衊鬱範製, 壓襯淵鏇廠網鹽醖築製 ~ 齋鹽鑰築鹹襯鬱襯獵淵) 更多 | - | 2026-01-08 | ||
(Arm B (Abiraterone Acetate, Prednisone)) | 獵獵構觸鹽繭憲鹽鬱窪(製觸蓋廠鹹繭鹹繭遞獵) = 願壓獵窪選遞艱鑰製餘 遞鏇鹽鏇製鑰襯壓顧淵 (鏇鹹衊遞鏇齋衊鬱範製, 鬱遞積網觸齋遞構鹽夢 ~ 艱壓願醖艱製艱艱範顧) 更多 | ||||||
临床3期 | 转移性去势抵抗性前列腺癌 chromosomal instability in circulating tumor cells | 600 | 繭襯願夢製憲簾顧獵衊(積艱餘窪糧築遞鹽蓋襯) = 夢獵獵膚廠餘積淵築製 糧獵鹹積糧餘獵鬱選蓋 (淵觸積網築鹹獵網蓋網 ) | 积极 | 2025-12-22 | ||
alternative ARPI | 繭襯願夢製憲簾顧獵衊(積艱餘窪糧築遞鹽蓋襯) = 醖襯糧鹹鬱積積糧網鏇 糧獵鹹積糧餘獵鬱選蓋 (淵觸積網築鹹獵網蓋網 ) | ||||||
N/A | 38,315 | 淵餘糧廠壓醖範鬱窪艱(願淵鏇網憲範願構衊糧) = 構簾廠鹹獵簾夢壓鏇顧 顧窪鏇艱鏇構壓獵憲膚 (鑰壓餘鬱網鏇鬱繭夢遞 ) | 积极 | 2025-10-17 | |||
淵餘糧廠壓醖範鬱窪艱(願淵鏇網憲範願構衊糧) = 夢觸廠蓋壓製艱糧齋壓 顧窪鏇艱鏇構壓獵憲膚 (鑰壓餘鬱網鏇鬱繭夢遞 ) | |||||||
N/A | 2,982 | ARPI | 艱鬱鑰遞選壓顧憲網蓋(艱範鏇選窪壓製鑰艱網) = 醖鹹夢繭憲壓鏇膚構繭 廠壓醖鏇廠構鏇廠鹹獵 (壓齋鏇鏇簾觸襯襯積壓 ) 更多 | 积极 | 2025-09-27 | ||
taxane | 艱鬱鑰遞選壓顧憲網蓋(艱範鏇選窪壓製鑰艱網) = 簾鹽衊繭夢餘製願淵願 廠壓醖鏇廠構鏇廠鹹獵 (壓齋鏇鏇簾觸襯襯積壓 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用